<DOC>
	<DOCNO>NCT02971189</DOCNO>
	<brief_summary>A prospective , single-arm , non-randomised study evaluate Librata device performance acute safety perform global endometrial ablation pre-menopausal woman heavy menstrual bleeding .</brief_summary>
	<brief_title>Librata Endometrial Ablation Device Treatment Reduce Menstrual Blood Loss Sites Across United Kingdom</brief_title>
	<detailed_description>4 clinical sits around UK aim recruit 40 woman study assess primary objective procedure success use Librata endometrial ablation device , define device success ( completion treatment cycle accord device specification ) occurrence intra-procedural complication . The investigator also assess secondary objective : 1 . Rates bleed month 3 , 6 12 measure menstrual pictogram 2 . Rate serious adverse device effect day 30 post-operatively 3 . Rates re-intervention menstrual relate bleeding pain and/or hysterectomy 6 12 month 4 . Rates patient satisfaction 6 12 month .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<criteria>1 . Refractory heavy menstrual bleeding definable organic cause 2 . Female subject ( include ) age 25 50 year 3 . Uterine sound measurement 6.0 10.0cm ( external o fundus ) . 4 . A minimum menstrual blood loss Menstrual Pictogram ( MP ) score ≥150 3 consecutive month prior study enrollment ; OR , MP score ≥150 one month woman either : least 3 prior month document fail medical therapy ; contraindication medical therapy ; refuse medical therapy 5 . Premenopausal enrollment determine FSH measurement ≤ 40 IU/L 6 . Not pregnant desire conceive time 7 . Subject agree use reliable form contraception . If hormonal birth control method use , subject must say method ≥ 3 month prior enrollment agrees remain hormonal regimen study participation . 8 . Able provide write informed consent use form approve review IRB/EC 9 . Subject agree followup schedule data collection requirement 10 . Subject literate demonstrate understand collect menstrual blood loss product , use Menstrual Pictogram ( MP ) diary Participants meet follow exclusion criterion enrol Study : 1 . Pregnancy subject desire become pregnant 2 . Endometrial hyperplasia confirm histology 3 . Presence active endometritis 4 . Active pelvic inflammatory disease 5 . Active sexually transmit disease ( STD ) , time ablation . Note : Treatment STD document chart serf sufficient evidence infection resolution . Subject may consider study enrollment . 6 . Presence bacteraemia , sepsis , active systemic infection 7 . Active infection genitals , vagina , cervix , uterus urinary tract time procedure 8 . Known/suspected gynecological malignancy within past 5 year 9 . Known clot defect bleed disorder 10 . Untreated/unevaluated cervical dyskaryosis ( except CIN I ) 11 . Known suspected abdominal/pelvic cancer 12 . Prior uterine surgery ( except low segment caesarean section ) interrupt integrity uterine wall ( e.g. , myomectomy classical cesarean section ) 13 . Previous endometrial ablation procedure 14 . Currently medication could thin myometrial muscle , longterm steroid use ( except inhaler nasal therapy asthma ) 15 . Currently anticoagulants 16 . Abnormal shape uterine cavity confirm transvaginal ultrasound scan +/ hysteroscopy specifically : Septate bicornuate uterus congenital malformation uterine cavity Submucosal fibroid ( grade 02 ) protrude &gt; 1cm uterine cavity Polyps &gt; 2cm maximum diameter Intramural subserosal fibroid great 3 cm 17 . Presence intrauterine device ( IUD ) subject unwilling removed time operative visit 18 . Presence implantable contraceptive device ( e.g . Essure Adiana ) . 19 . Subject currently hormonal birth control therapy unwilling use nonhormonal birth control postablation . 20 . Subject want concomitant hysteroscopic sterilization . 21 . Subject within 6weeks postpartum . 22 . Any general health condition , opinion Investigator , could represent increase risk subject 23 . Any subject currently participate considers future participation</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>